Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
realgar-indigo naturalis formula + cisplatin
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital of Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Realgar-Indigo Naturalis Formula (RIF) + cisplatin is a combination therapy being investigated for the treatment of osteosarcoma. RIF is a traditional Chinese medicine formula primarily composed of realgar (containing arsenic sulfide, $As_4S_4$), Indigo naturalis, and Salvia miltiorrhiza. While RIF is traditionally used and approved in China for acute promyelocytic leukemia (APL), researchers at The First Affiliated Hospital of Sun Yat-sen University are exploring its synergistic potential with cisplatin in solid tumors like osteosarcoma. The mechanism of action involves a dual approach: cisplatin induces DNA cross-linking and damage, while the arsenic components of RIF promote the generation of reactive oxygen species (ROS), inhibit thioredoxin reductase, and trigger mitochondrial-mediated apoptosis. This combination is designed to overcome chemoresistance and enhance the pro-apoptotic effects of standard chemotherapy in bone malignancies.
- Other names
- Realgar-Indigo Naturalis Formula plus cisplatinRIF plus cisplatin
02
Targets
PML-RARA (PML-retinoic acid receptor alpha fusion protein)DNA
Beyond the preview
Go deeper on realgar-indigo naturalis formula + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on realgar-indigo naturalis formula + cisplatin.